Review
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Jul 15, 2023; 14(7): 977-994
Published online Jul 15, 2023. doi: 10.4239/wjd.v14.i7.977
Implications of receptor for advanced glycation end products for progression from obesity to diabetes and from diabetes to cancer
Andrea Garza-Campos, José Roberto Prieto-Correa, José Alfredo Domínguez-Rosales, Zamira Helena Hernández-Nazará
Andrea Garza-Campos, José Roberto Prieto-Correa, Programa de Doctorado en Ciencias en Biología Molecular en Medicina, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico
Andrea Garza-Campos, José Roberto Prieto-Correa, José Alfredo Domínguez-Rosales, Zamira Helena Hernández-Nazará, Departamento de Biología Molecular y Genómica, Instituto de Investigación en Enfermedades Crónico-Degenerativas, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico
Author contributions: Garza-Campos A and Prieto-Correa JR contributed to the writing, reviewing, and editing of the manuscript; Prieto-Correa JR and Domínguez-Rosales JA prepared the table; Garza-Campos A and Hernández-Nazará ZH prepared the figures; Domínguez-Rosales JA contributed to the writing and performed the majority of the reviewing and editing of the manuscript; Hernández-Nazará ZH and Domínguez-Rosales JA conceptualized the study and designed the outline for the paper; Hernández-Nazará ZH wrote the first draft; and all authors read and approved the final manuscript.
Supported by the Founding Proyectos de Impulso a la Investigación to Hernandez-Nazara ZH from Universidad de Guadalajara, Mexico, No. PIN 2020-I.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zamira Helena Hernández-Nazará, MD, PhD, Departamento de Biología Molecular y Genómica, Instituto de Investigación en Enfermedades Crónico-Degenerativas, Universidad de Guadalajara, Sierra Mojada 950, Col. Independencia C.P. 44350, Guadalajara 44340, Jalisco, Mexico. zamirahelena@yahoo.com.mx
Received: January 9, 2023
Peer-review started: January 9, 2023
First decision: January 17, 2023
Revised: January 31, 2023
Accepted: April 17, 2023
Article in press: April 17, 2023
Published online: July 15, 2023
Processing time: 184 Days and 15.6 Hours
Core Tip

Core Tip: The receptor for advanced glycation products (RAGE) is involved in every stage of the pathophysiological pathways that lead to the progression of obesity, type 2 diabetes, and cancer. This article provides a focused discussion on the stages of obesity leading to the development of metabolic diseases and provides a broad overview of the contribution of RAGE to the development of diabetes and cancer.